Oaktree Acquisition Corp. III Life Sciences (OACC) Invested Capital (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences filings provide 3 years of Invested Capital readings, the most recent being -$7.2 million for Q1 2026.

  • Quarterly Invested Capital fell 10.85% to -$7.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$7.2 million through Mar 2026, down 10.85% year-over-year, with the annual reading at -$6.8 million for FY2025, 11.45% down from the prior year.
  • Invested Capital hit -$7.2 million in Q1 2026 for Oaktree Acquisition Corp. III Life Sciences, down from -$6.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at -$6.1 million in Q4 2024 and bottomed at -$7.2 million in Q1 2026.
  • Average Invested Capital over 3 years is -$6.6 million, with a median of -$6.7 million recorded in 2025.
  • The largest annual shift saw Invested Capital decreased 11.45% in 2025 before it dropped 10.85% in 2026.
  • Oaktree Acquisition Corp. III Life Sciences' Invested Capital stood at -$6.1 million in 2024, then dropped by 11.45% to -$6.8 million in 2025, then fell by 6.74% to -$7.2 million in 2026.
  • Per Business Quant, the three most recent readings for OACC's Invested Capital are -$7.2 million (Q1 2026), -$6.8 million (Q4 2025), and -$6.8 million (Q3 2025).